On the same trading day, on the same exchange, in the same sector — one stock closed at its all-time high while another lost Tk 98 of its value in a single session. ASIATICLAB ended Thursday at Tk 126.00, up 4.65% on volume 1.45 times its 90-day average. GLAXOSMITH ended at Tk 1,415, down 6.46% from Wednesday’s Tk 1,513.
Both are listed pharmaceuticals. Both trade on the DSE Main Board. Both answer to the same regulator. And yet today’s tape treated them as if they belonged to two different economies.
That divergence is no longer noise. Look at the cumulative numbers and a different picture comes into focus.
The Numbers That Make the Split Impossible to Ignore
ASIATICLAB has now returned 290% over twelve months. Trailing-twelve-month revenue grew 52.23% to Tk 2.24 billion, and net income climbed 40.78% to Tk 378.08 million. The stock has gained 30.3% in the past month alone, and 15.0% over just the last five sessions. Today’s close marks a fresh 52-week high after a recovery rally from the May 6 crash and the May 19 reset above Tk 117 carried the stock straight into new territory.
GLAXOSMITH closed today not on a corporate disclosure, not on an earnings miss, not on any reported news — but on what looks like institutional repositioning. A 6.46% single-session decline at the Tk 1,500 price band is the kind of move that, on most DSE sessions, would brush against the daily circuit breaker. It got there without a headline. That is what happens when a sell programme runs on conviction.
The DSEX gained just 0.28% to close at 5,226 on a relatively quiet day. The benchmark moved within a 30-point range. Yet inside that calm sat one of the widest intra-sector spreads of the year. So far in May, the pharmaceutical sector has produced three different rallies and three different crashes. Today is the cleanest example yet of which side of the sector is rewarded and which side is punished.
Why Asiatic Labs’ Rally Is Different This Time
Three fiscal years ago, Asiatic Laboratories was a struggling company. FY2023 revenue declined 12.46%. Earnings dropped 23.35%. The chart looked like a small Bangladeshi manufacturer running into the wall of a domestic market that had stopped growing.
What changed was the export pivot. By FY2024, revenue growth turned positive at 7.44%. By FY2025, it accelerated to 27.45%. Trailing twelve months now shows 52.23% growth. The transformation came from selling generic formulations into Afghanistan, Central Asia, and African markets where Bangladeshi manufacturers can compete on price against Indian and Chinese alternatives without facing the LDC-graduation timing pressure that will eventually arrive.
That is the story the market is now pricing. Today’s Tk 126 close at a P/E of 38.98 is not a value rating. It is a growth rating, the kind ordinarily reserved for technology stocks, applied to a company that turned a structural domestic problem into an export-driven expansion. The 79.56 RSI says the rally is short-term overbought. It does not say the thesis is wrong.
What the GLAXOSMITH Crash Says About MNC Consumer Pharma
GLAXOSMITH does not run on that engine. The remaining listed entity is a consumer-health and MNC-branded operation focused on the domestic premium segment after the original consumer division left the listing for the Unilever Consumer Care vehicle. Domestic premium is exactly the segment under pressure right now.
Real wages have not kept pace with the inflation cycle that began in 2024. Consumer-staple premium brands are losing volume to cheaper local generics — including, ironically, generics from companies like Asiatic Labs that are also pivoting domestically. The MNC parent group has been restructuring globally and the Bangladesh listing carries the same uncertainty. Investors who can read a sector rotation are not waiting for the formal announcement to act.
A 6.46% single-session drop on no news is the action. The structural read is the message.
The Risk in Calling This the Final Verdict
Two cautions before the conclusion writes itself. ASIATICLAB at RSI 79.56 with a P/E near 39 is in the zone where any negative export-data print or any rumour of margin compression triggers a correction. Today’s gain is the seventh straight session of upward pressure, and the whipsaw pattern of May 6 is the obvious template for what disappointment looks like.
GLAXOSMITH at Tk 1,415 may also be oversold. A clean MNC restructuring statement, or a parent-company announcement of continued investment, could reverse a significant portion of today’s loss in a single session.
But the direction of travel is now visible. After yesterday’s pre-Eid positioning session, the pharma sector has shown the market exactly what it wants to own and exactly what it wants to sell. Export-driven generics on one side. MNC consumer-brand pharma on the other. One trade. Two outcomes. The same sector classification.